Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study

被引:111
作者
Ascher, B. [1 ]
Hoffmann, K. [2 ]
Walker, P. [3 ]
Lippert, S. [4 ]
Wollina, U. [5 ]
Havlickova, B. [4 ]
机构
[1] Clin Aesthet Surg IENA, Paris, France
[2] Ruhr Univ Bochum, Dept Dermatol, Bochum, Germany
[3] KYTHERA Biopharmaceut Inc, Calabasas, CA USA
[4] Bayer HealthCare, Global Clin Dev Dermatol, Berlin, Germany
[5] Acad Teaching Hosp Dresden Friedrichstadt, Dept Dermatol & Allergol, Dresden, Germany
关键词
AGING FACE; LIPOSUCTION; TISSUE; COMPLICATIONS; INFECTIONS; ULTRASOUND;
D O I
10.1111/jdv.12377
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100227 [皮肤病学];
摘要
Background Unwanted submental fat (SMF) may result in an unattractive chin profile and dissatisfaction with appearance. An approved and rigorously tested non-surgical method for SMF reduction is lacking. ObjectiveTo evaluate the efficacy and safety of ATX-101 for the pharmacological reduction of unwanted SMF in a phase III randomized, double-blind, placebo-controlled study. MethodsPatients (n=360) with moderate or severe SMF were randomized to receive ATX-101 1 or 2mg/cm(2) or placebo injected into their SMF for up to four treatments 28days apart, with a 12-week follow-up. Coprimary efficacy endpoints were the proportions of treatment responders, defined as a 1-point reduction in SMF on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS), and those satisfied with their appearance in association with their face and chin after treatment on the Subject Self-Rating Scale (SSRS score 4). Secondary efficacy endpoints included a 1-point improvement in SMF on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS) and changes in the Patient-Reported Submental Fat Impact Scale (PR-SMFIS). Additional patient-reported outcomes and changes in the Skin Laxity Rating Scale were recorded. Adverse events (AEs) and laboratory test results were monitored. ResultsCompared with placebo, a greater proportion of patients treated with ATX-101 1 and 2mg/cm(2) showed a 1-point improvement in CR-SMFRS (58.3% and 62.3%, respectively, vs. 34.5% with placebo; P<0.001) and patient satisfaction (SSRS score 4) with the appearance of their face and chin (68.3% and 64.8%, respectively, vs. 29.3%; P<0.001). Patient-reported secondary efficacy endpoints showed significant improvements in SMF severity (PR-SMFRS; P=0.009 for ATX-101 1mg/cm(2), P<0.001 for ATX-101 2mg/cm(2) vs. placebo) and emotions and perceived self-image (PR-SMFIS; P<0.001). No overall worsening of skin laxity was observed. AEs were mostly transient, mild to moderate in intensity and localized to the treatment area. ConclusionATX-101 was effective and well tolerated, and may be an alternative to surgery for patients desiring improvement of their submental profile.
引用
收藏
页码:1707 / 1715
页数:9
相关论文
共 28 条
[1]
Abraham MT, 2012, LIPOSUCTION FACE NEC
[2]
Surgical site infections after post-bariatric abdominoplasty and flank liposuction: a case-control study focusing on the quantity of tissue removed [J].
Araco, Antonino ;
Gravante, Gianpiero ;
Gentile, Pietro ;
Cervelli, Valerio .
SURGERY TODAY, 2012, 42 (01) :97-99
[3]
Ascher B, 2008, INJECTION TREATMENTS, P329
[4]
Fatal and near-fatal complications of liposuction [J].
Barillo, DJ ;
Cancio, LC ;
Kim, SH ;
Shirani, KZ ;
Goodwin, CW .
SOUTHERN MEDICAL JOURNAL, 1998, 91 (05) :487-492
[5]
Principles of soft tissue augmentation for the aging face [J].
Burgess, Cheryl M. .
CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) :349-355
[6]
Co Abigail C, 2007, J Cosmet Dermatol, V6, P250
[7]
Non-Invasive, External Ultrasonic Lipolysis [J].
Coleman, Kyle M. ;
Coleman, William P., III ;
Benchetrit, Arie .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2009, 28 (04) :263-267
[8]
Dover J, 2012, 21 ANN C EUR AC DERM
[10]
Gallagher D, 1996, AM J EPIDEMIOL, V143, P228, DOI 10.1093/oxfordjournals.aje.a008733